GT103

GT103 (50 μg/mL; overnight) binds to formalin-fixed, paraffin-embedded human NSCLC tumor tissue sections, with no detectable binding to formalin-fixed, paraffin-embedded normal human lung tissue sections^[1].
GT103 (200 μg/mL; 2 h) increases plasma membrane calreticulin expression by approximately 2-fold in NCI-H460 and A549 human lung cancer cells, with no change in total cellular calreticulin levels^[1].
GT103 (200 μg/mL; 24 h) significantly increases C_3b/iC_3b deposition on NCI-H460 and A549 human lung cancer cells via the classical complement pathway, as deposition is reduced in C1q-depleted but not Factor B-depleted serum^[1].
GT103 (200 μg/mL; 2 h) significantly increases C1q surface binding to NCI-H460 human lung cancer cells, which is dependent on the antibody's Fc region^[1].
GT103 (250 μg/mL; 4 h) significantly enhances macrophage-mediated ADCP of NCI-H460 human lung cancer cells in vitro^[1].
GT103 (200 μg/mL; 1-h pre-treatment) significantly increases Syk kinase phosphorylation in human B cells in vitro, in a complement-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.